Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Reifenberg

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical and Translational Science|February 22, 2025
Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's diseaseAbigail Samuels, Kei Irie, Tomoyuki Mizuno, et al.
Therapeutic Drug Monitoring|June 3, 2025
Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World DataKei Irie, Phillip Minar, Jack Reifenberg, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
Model-informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Clinical Pharmacokinetics|August 30, 2025
Hybrid Population Pharmacokinetic-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Hybrid Population PK-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Clinical Pharmacology and Therapeutics|November 5, 2025
Model-Informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 4, 2023
Lung function and secondhand smoke exposure among children with cystic fibrosis: A Bayesian meta-analysisJack Reifenberg, Emrah Gecili, Teresa Pestian, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical and Translational Science|February 22, 2025
Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's diseaseAbigail Samuels, Kei Irie, Tomoyuki Mizuno, et al.
Therapeutic Drug Monitoring|June 3, 2025
Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World DataKei Irie, Phillip Minar, Jack Reifenberg, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
Model-informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Clinical Pharmacokinetics|August 30, 2025
Hybrid Population Pharmacokinetic-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Hybrid Population PK-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Clinical Pharmacology and Therapeutics|November 5, 2025
Model-Informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 4, 2023
Lung function and secondhand smoke exposure among children with cystic fibrosis: A Bayesian meta-analysisJack Reifenberg, Emrah Gecili, Teresa Pestian, et al.
Pageof 1